Retraction: Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells (Proceedings of the National Academy of Sciences of the United States of America (2014) 112 (E21-E29) DOI: 10.1073/pnas.1417015112);Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 1, 2015, Pages E21-E29

  Li, Jing ^a,d   Csibi, Alfredo ^a,e   Yang, Sun ^b   Hoffman, Gregory R ^a,f   Li, Chenggang ^b   Zhang, Erik ^b   Yu, Jane J ^b   Blenis, John ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d PFIZER INC   (United States)

^e Infinity Pharmaceuticals Inc   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Glutaminase; Hsp90; Inhibitors; mTORC1; Synthetic lethality

Indexed keywords

17 N ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 AMINO 6 CHLORO 9 [(4 METHOXY 3,5 DIMETHYL 2 PYRIDINYL)METHYL]PURINE; BIS 2 (5 PHENYLACETAMIDO 1,2,4 THIADIAZOL 2 YL)ETHYL SULFIDE; GLUTAMATE DEHYDROGENASE; GLUTAMINASE; GLUTAMINE; GLUTATHIONE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HYDROLASE INHIBITOR; LUMINESPIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; TUBERIN; UNCLASSIFIED DRUG; BENZOQUINONE DERIVATIVE; BIS-2-(5-PHENYLACETAMIDO-1,2,4-THIADIAZOL-2-YL)ETHYL SULFIDE; MACROCYCLIC LACTAM; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MOLECULAR LIBRARY; MULTIPROTEIN COMPLEX; SULFIDE; TANESPIMYCIN; TARGET OF RAPAMYCIN KINASE; THIADIAZOLE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER REGRESSION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; LETHALITY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; RAT; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UNFOLDED PROTEIN RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL SHAPE; CELL SURVIVAL; DEFICIENCY; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; MOLECULAR LIBRARY; MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; PHARMACOLOGY; PHENOTYPE; TUBEROUS SCLEROSIS; TUMOR CELL LINE;

MAMMALIA;

ANIMALS; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; GLUTAMATE DEHYDROGENASE; GLUTAMINASE; GLUTAMINE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; OXIDATION-REDUCTION; PHENOTYPE; SIROLIMUS; SMALL MOLECULE LIBRARIES; SULFIDES; THIADIAZOLES; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920431299     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.2220405120     Document Type: Erratum

References (40)

1. Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10(5):307-318.
2. Menon S, Manning BD (2008) Common corruption of the mTOR signaling network in human tumors. Oncogene 27(Suppl 2):S43-S51.
3. Bissler JJ, et al. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358(2):140-151.
4. Marsh DJ, et al. (2008) Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 5(6):357-361.
5. Li J, Kim SG, Blenis J (2014) Rapamycin: One drug, many effects. Cell Metab 19(3):373-379.
6. Ron D, Walter P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8(7):519-529.
7. Marcu MG, et al. (2002) Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol 22(24):8506-8513.
8. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 136(5):823-837.
9. Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat Rev Mol Cell Biol 11(7):515-528.
10. Tabas I, Ron D (2011) Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 13(3):184-190.
11. Ozcan U, et al. (2008) Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 29(5):541-551.
12. Kang YJ, Lu MK, Guan KL (2011) The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis. Cell Death Differ 18(1):133-144.
13. Choo AY, et al. (2010) Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell 38(4):487-499.
14. Ohji G, et al. (2006) Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin. J Biochem 139(1):129-135.
15. Sain N, et al. (2006) Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 5(5):1197-1208.
16. Robinson MM, et al. (2007) Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 406(3):407-414.
17. Wise DR, Thompson CB (2010) Glutamine addiction: A new therapeutic target in cancer. Trends Biochem Sci 35(8):427-433.
18. Boren J, Brindle KM (2012) Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation. Cell Death Differ 19(9):1561-1570.
19. Hayashi-Nishino M, et al. (2009) A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation. Nat Cell Biol 11(12):1433-1437.
20. Ylä-Anttila P, Vihinen H, Jokitalo E, Eskelinen EL (2009) 3D tomography reveals connections between the phagophore and endoplasmic reticulum. Autophagy 5(8): 1180-1185.
21. Hailey DW, et al. (2010) Mitochondria supply membranes for autophagosome biogenesis during starvation. Cell 141(4):656-667.
22. Boulares AH, et al. (1999) Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274(33):22932-22940.
23. Wang JB, et al. (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18(3):207-219.
24. De Raedt T, et al. (2011) Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 20(3):400-413.
25. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 105(45):17414-17419.
26. Thoreen CC, Sabatini DM (2009) Rapamycin inhibits mTORC1, but not completely. Autophagy 5(5):725-726.
27. Li C, et al. (2006) Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase. J Biol Chem 281(15):10214-10221.
28. Csibi A, et al. (2013) The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153(4):840-854.
29. Gao P, et al. (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239):762-765.
30. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y (2007) Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 178(1):93-105.
31. Lora J, et al. (2004) Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells. Eur J Biochem 271(21):4298-4306.
32. Malhotra JD, Kaufman RJ (2007) Endoplasmic reticulum stress and oxidative stress: A vicious cycle or a double-edged sword? Antioxid Redox Signal 9(12):2277-2293.
33. Kim J, et al. (2008) Overexpressed cyclophilin B suppresses apoptosis associated with ROS and Ca2+ homeostasis after ER stress. J Cell Sci 121(Pt 21):3636-3648.
34. Weinberg F, et al. (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107(19):8788-8793.
35. Wellen KE, Thompson CB (2010) Cellular metabolic stress: Considering how cells respond to nutrient excess. Mol Cell 40(2):323-332.
36. Barrott JJ, Haystead TA (2013) Hsp90, an unlikely ally in the war on cancer. FEBS J 280(6):1381-1396.
37. LoRusso PM, et al. (2012) Accelerating cancer therapy development: The importance of combination strategies and collaboration. Summary of an institute of medicine workshop. Clin Cancer Res 18(22):6101-6109.
38. Chandarlapaty S, et al. (2010) Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab- resistant tumors and suppress their growth. Oncogene 29(3):325-334.
39. Jhaveri K, Taldone T, Modi S, Chiosis G (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823(3):742-755.
40. Durán RV, et al. (2012) Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 47(3):349-358.